Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2

 Saman Saadat,  

View ORCID ProfileZahra Rikhtegaran-Tehrani,  View ORCID ProfileJames Logue, Michelle Newman,  View ORCID ProfileMatthew B Frieman, Anthony D. Harris,  View ORCID ProfileMohammad M. Sajadi

doi: https://doi.org/10.1101/2021.01.30.21250843

This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

PDF: https://www.medrxiv.org/content/10.1101/2021.01.30.21250843v1.full.pdf

Abstract

Coronavirus disease 2019 (COVID-19) vaccine shortages have led some experts and countries to consider untested dosing regimens. We studied antibody responses to a single dose of the Pfizer-BioNTech or Moderna vaccines in healthcare workers (HCW) with laboratory-confirmed COVID-19 infection and compared to them to antibody responses of HCW who were IgG negative to SARS-CoV-2 spike protein. HCW with prior COVID-19 showed clear secondary antibody responses to vaccination with IgG spike binding titers rapidly increasing by 7 days and peaking by days 10 and 14 post-vaccination. At all time points tested, HCW with prior COVID-19 infection showed statistically significant higher antibody titers of binding and functional antibody compared to HCW without prior COVID-19 infection (p<.0001for each of the time points tested). In times of vaccine shortage, and until correlates of protection are identified, our findings preliminarily suggest the following strategy as more evidence-based: a) a single dose of vaccine for patients already having had laboratory-confirmed COVID-19; and b) patients who have had laboratory-confirmed COVID-19 can be placed lower on the vaccination priority list.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

ADH supported by CDC grant U01CK000556-02-01.

https://www.medrxiv.org/content/10.1101/2021.01.30.21250843v1